{"organizations": [], "uuid": "d52b216a3e9220a3dc37922d3c22dd8dd0094747", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sanofi-announes-some-positive-phas/brief-sanofi-announes-some-positive-phase-3-trials-for-dupixent-idUSFWN1SM1ID", "country": "US", "domain_rank": 408, "title": "BRIEF-Sanofi announes some positive Phase 3 trials for Dupixent速 (dupilumab)", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.982, "site_type": "news", "published": "2018-05-16T13:10:00.000+03:00", "replies_count": 0, "uuid": "d52b216a3e9220a3dc37922d3c22dd8dd0094747"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sanofi-announes-some-positive-phas/brief-sanofi-announes-some-positive-phase-3-trials-for-dupixent-idUSFWN1SM1ID", "ord_in_thread": 0, "title": "BRIEF-Sanofi announes some positive Phase 3 trials for Dupixent速 (dupilumab)", "locations": [], "entities": {"persons": [{"name": "dupixent", "sentiment": "none"}, {"name": "sanofi", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - Sanofi:\n* Dupixent速 (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis\n* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018\n* A pivotal Phase 3 trial evaluating Dupixent (速)(dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary and key secondary endpoints\n* In the trial, treatment with Dupixent as monotherapy significantly improved measures of overall disease severity, skin clearing, itching, and certain health-related quality of life measures\n* Dupixent is the first and only biologic to show positive results in this patient population, adds Sanofi\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T13:10:00.000+03:00", "crawled": "2018-05-17T14:22:21.008+03:00", "highlightTitle": ""}